Carcinogenesis is a multistep process, and tumors frequently harbor multiple mutations
regulating genome integrity, cell division and death. The integrity of cellular genome is …

Motivated by the explosion of molecular data on humans-particularly data associated with
individual patients-and the sense that there are large, as-yet-untapped opportunities to use …

Although PARP inhibitors (PARPi) target homologous recombination defective tumours,
drug resistance frequently emerges, often via poorly understood mechanisms. Here, using …

The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been
reported in single populations, with the majority of reports focused on White in Europe and …

Background: Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy,
responsible for 13 000 deaths per year in the United States. Risk prediction based on …

Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer,
but the average magnitude of these risks is uncertain and may depend on the context …

The cloning of the breast cancer susceptibility genes BRCA1 and BRCA2 nearly two
decades ago helped set in motion an avalanche of research exploring how genomic …

The contribution of BRCA1 and BRCA2 to inherited breast cancer was assessed by linkage
and mutation analysis in 237 families, each with at least four cases of breast cancer …

This 2004 volume in the World Health Organization series on histologic and genetic typing
of human tumors covers tumors of the kidney, urinary system, prostate, testis and …

Background Carriers of germ-line mutations in BRCA1 and BRCA2 from families at high risk
for cancer have been estimated to have an 85 percent risk of breast cancer. Since the …